Contineum Therapeutics/CTNM

$16.11

1.57%
-
1D1W1MYTD1YMAX

About Contineum Therapeutics

Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation, and immunology (NI&I) indications with high unmet need. Its pipeline includes PIPE-791, CTX-343, and PIPE-307. Its lead asset, PIPE-791, is novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) in development for idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis (Progressive MS). The Company is developing CTX-343, a peripherally restricted LPA1R antagonist to further expand clinical indications involving LPA1R antagonism. Its second drug candidate, PIPE-307, is a novel, small molecule, selective inhibitor of M1R, which is in clinical development for the potential treatment of depression and relapse remitting MS (RRMS).

Ticker

CTNM

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Carmine Stengone

Employees

31

Headquarters

San diego, United States

CTNM Metrics

BasicAdvanced
$412M
Market cap
17.70
P/E ratio
$0.90
EPS
-
Beta
-
Dividend rate
$412M
$16.09
$13.27
23.287
21.248
17.698
8.231
3.301
21.736
193.68%

What the Analysts think about CTNM

Analyst Ratings

Majority rating from 3 analysts.
Buy

Price Targets

Average projection from 3 analysts.
73.81% upside
High $30.00
Low $25.00
$16.11
Current price
$28.00
Average price target

CTNM Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-100%
Net income
-$7.7M
-125.33%
Profit margin
0%
-100%

CTNM Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 671.74%
QuarterlyAnnual
Q1 24
Q2 24
Actual
-$3.55
-
Expected
-$0.46
-$0.35
Surprise
671.74%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Contineum Therapeutics stock?

Contineum Therapeutics (CTNM) has a market cap of $412M as of May 24, 2024.

What is the P/E ratio for Contineum Therapeutics stock?

The price to earnings (P/E) ratio for Contineum Therapeutics (CTNM) stock is 17.7 as of May 24, 2024.

Does Contineum Therapeutics stock pay dividends?

No, Contineum Therapeutics (CTNM) stock does not pay dividends to its shareholders as of May 24, 2024.

When is the next Contineum Therapeutics dividend payment date?

Contineum Therapeutics (CTNM) stock does not pay dividends to its shareholders.

What is the beta indicator for Contineum Therapeutics?

Contineum Therapeutics (CTNM) does not currently have a Beta indicator.

What is the Contineum Therapeutics stock price target?

The target price for Contineum Therapeutics (CTNM) stock is $28, which is 73.81% above the current price of $16.11. This is an average based on projections from 3 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Contineum Therapeutics stock

Buy or sell Contineum Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing